Out-licensing: Drug Delivery/Intravesical & Metabolism

Latest: Watch here for details of new products and services.

About Us: Innovaro Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Pay-per-Click New!; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Innovaro Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Innovaro Pharmalicensing
is a division of
Innovaro Europe Ltd

Up-to-date access to technology licensing opportunities worldwide.

Displaying 1..1 of 1 - per page
Order by

Obese patients are unable to transport leptin from the blood into the brain because of the resistance at the blood brain barrier. More

Displaying 1..1 of 1 - per page
Order by

Therapeutic target: Anorexia; Anti-oxidant; Appetite; Bulimia nervosa; Cachexia; Cirrhosis; Diabetes type I; Diabetes type II; Diabetic complications; Fabry's disease; Gallbladder disorder (other); Gallstones; Gaucher's disease; Hepatic protectors; Hepatic protectors; Hypercholesterolemia; Hyperparathyroidism; Hypertriglyceridemia; Liver cancer; Liver disorders (other); Metabolic disorder (other); Mineral supplement; Obesity; Weight loss
Development phase: Early Stage; Preclinical; Phase I; Phase I/II; Phase II; Phase III; Phase III/IV; Preregistration; Registered

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Innovaro Pharmalicensing current industry press releases.